tacrolimus (anhydrous)

(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone

QJJXYPPXXYFBGM-LFZNUXCKSA-N CHEBI:61049 10 Reactome links 6 studies

6 Observed studies

6 Observed diff profiles

10 Reactome pathways

Metabolite details

Identifier: QJJXYPPXXYFBGM-LFZNUXCKSA-N
InChI Key: QJJXYPPXXYFBGM-LFZNUXCKSA-N
IUPAC name: (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
Preferred name: tacrolimus (anhydrous)
INN name: tacrolimus
Synonym: (−)-FK 506
ChEBI: CHEBI:61049

Reactome pathways

R-HSA-1168372 - Downstream signaling events of B Cell Receptor (BCR)
R-HSA-1280218 - Adaptive Immune System
R-HSA-1643685 - Disease
R-HSA-168256 - Immune System
R-HSA-2025928 - Calcineurin activates NFAT
R-HSA-5663205 - Infectious disease
R-HSA-9679191 - Potential therapeutics for SARS
R-HSA-9679506 - SARS-CoV Infections
R-HSA-9824446 - Viral Infection Pathways
R-HSA-983705 - Signaling by the B Cell Receptor (BCR)

Observed in studies

Observed in differential profiles